Previous data from Misale et al., as well as our own data, showed that tumours selecting KRAS mutations during acquired resistance development under anti‐EGFR therapy can be successfully treated by vertical inhibition of EGFR and MEK [9, 10, 43]. The gene discussed is MAP2K7; the disease is neoplasm.